1Kubota K, Kawahara M, Ogawara M, et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study [ J ]. Lancet Oncol, 2008, 9 ( 12 ) : 1135-1142.
2Radhakrishnan A, Bitran JD, Milton DT, et al. Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial[J]. J Chemother, 2009,21('4) :439-444.
3Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations [ J ]. Radiographics, 2008,28 (2) : 329-344.
4Fujita J, Ohtsuki Y, Bandoh S, et al. Elevation of cytokeratin 19 fragment ( CYFRA 21-1 ) in serum of patient with radiation pneumonitis: possible marker of epithelial cell damage [ J ]. Respir Med, 2004,98(4) :294-300.
5Nisman B, Biran H, Heching N, et al. Prognostic role of serum cytoeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival [ J ]. Br J Cancer, 2008,98( 1 ) :77-79.
6Aridizzoni A, Cafferata MA, Tiseo M, et al. Decline in serum carei- noembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer [ J ]. Cancer, 2006, 107 ( 12 ) : 2842 -2849.
